ZG-802 Phase IIa Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-802 in patients with Underactive Bladder

Tomioka Yusuke0 个研究点目标入组 150 人开始时间: 2023年4月29日最近更新: 2024年4月1日

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•1) Patients who have any symptoms of slow stream, hesitancy or straining to void for more than 90 days before the Screening date
•2) Patients who meet all the specified criteria of uroflowmetry and transabdominal ultrasonographya for both Screening and Baseline
•3) Patients with a score of specified points or more in any item of voiding symptoms (intermittency, slow stream and straining to void) of the International Prostate Symptom Score for Baseline
•4) Patients aged 18 years or older at the time of informed consent

排除标准

•1) Patients with a urgency score of 2 or more on the Overactive Bladder Symptom Questionnaire during the observation period
•2) Patients with bladder outlet obstruction who meet one or more of the following
•a) Female patients with pelvic organ prolapse of stage III or higher in the POP - Q stage classification
•b) Male patients with Intravesical prostatic protrusion >= 10 mm or prostate volume >= 30 mL
•c) Male patient with prostate cancer
•d) Patients with severe urethral stricture requiring surgery
•e) Patients who do not fall under a) to d) but are judged by investigators to have a clinically problematic bladder outlet obstruction
•3) Patients with urethral diverticulum
•4) Patients with ureteral calculus, vesical calculus or urethral calculus
•5) Patients with progressive neurodegenerative disease (e.g. Parkinson's disease, multiple system atrophy, progressive supranuclear palsy)
•6) Patients with neurological diseases other than progressive neurodegenerative diseases who show a clear exacerbation or recovery tendency (e.g., cerebrovascular disease, normal pressure hydrocephalus, cerebral white matter lesion, spinal cord injury, multiple sclerosis) , vascular disease of spinal cord, lumbar diseases (spinal canal stenosis, degenerative spondylolisthesis, lumber vertebrae herniated disk, etc.), diabetic neuropathy)
•7) Patients with increased pelvic floor muscle activity during urination (e.g., striated sphincter incoordination, Fowler's syndrome, pelvic floor muscle spasms)
•8) Patients with or suspected of having a symptomatic urinary tract infection or genital infection
•9) Patients with severe urinary organ pain
•10) Patients who have recieved certain treatments, patients who have been treated within certain period, or patients who are expected to be treated them during the treatment period
•11) Patients who have changed the dosage and administration of certain drugs within certain period, or patients who are expected to change during the treatment period
•12) Patients who are encouraged to urinate by applying pressure from outside the body such as the Crede's procedure, valsalva maneuver or by tapping
•13) Patients with a history of surgery to the pelvis and lower urinary tract, or expected to be performed during the treatment period
•14) Patients judged by the investigator to be unable to properly record the bladder diary of Baseline
•15) Patients who have used other investigational drugs within the past 30 days including the screening date, or patients whose period between the time of use of other investigational drugs and the screening date is within 5 times the half-life of the relevant investigational drug
•16) Patients with clinically significant heart disease, liver disease, renal disease, blood disease, etc.
•17) Patients with allergy to certain chemical substances
•18) Patients with malignant tumors. Patients who have been treated for malignant tumors or have had a malignant tumor, in the past 5 years including the baseline date.
•19) Female patients who are pregnant or breastfeeding. Male patients and premenopausal female patients who are unable to use adequate contraception during the study period and for 7 days after the end of study drug administration.
•20) Patients with a history of acute alcohol intoxication or alcohol dependence within the past 1 year including the baseline date, or patients with a history of drug and chemical substance abuse in the past
•21) Patients who are hospitalized during the o

研究者

发起方

Tomioka Yusuke

相似试验

进行中（未招募）

不适用

A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccines Containing 3.75 mcg or 7.5 mcg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects - Dose reductioAvian influenza

EUCTR2009-012385-31-PLovartis Vaccines and Diagnostics S.r.l.770

进行中（未招募）

1 期

A study to evaluate the effect of trilaciclib on overall survival in patients with metastatic non-small cell lung cancer receiving docetaxelMetastatic Non small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-000186-32-ITG1 Therapeutics Inc.146

进行中（未招募）

1 期

EUCTR2021-000186-32-ESG1 Therapeutics, Inc.146

进行中（未招募）

1 期

EUCTR2021-000186-32-PLG1 Therapeutics, Inc.146

尚未招募

2 期

An evaluation of a medicinal herb as a treatment for Parkinson’s diseaseParkinson´s disease

RBR-6t4j85Hospital Universitário Clementino Fraga Filho - UFRJ